```html

Xerophthalmic Conjunctivitis

What is Xerophthalmic Conjunctivitis?

Xerophthalmic conjunctivitis is an inflammation of the conjunctiva (the thin, transparent membrane that lines the eyelid inner surface and covers the white of the eye) that occurs in the setting of chronic dryness of the ocular surface. The term “xerophthalmic” comes from the Greek “xero” (dry) and “ophthalmos” (eye). When the tear film becomes insufficient or of poor quality, the conjunctiva becomes irritated, inflamed, and may develop a characteristic dry, scaly appearance. The condition is most often seen in people with severe dry‑eye disease, but it can also be a secondary manifestation of systemic or ocular disorders that impair tear production or tear stability.

Because the conjunctiva is a protective barrier, its inflammation can lead to discomfort, visual disturbance, and increased risk of infection. Prompt recognition and treatment are essential to preserve ocular health and quality of life.

Common Causes

The underlying problem is insufficient lubrication, but several distinct diseases or environmental factors can produce xerophthalmic conjunctivitis. The most common contributors include:

• Severe aqueous‑deficient dry eye (Sjögren’s syndrome): Autoimmune destruction of lacrimal glands.
• Meibomian gland dysfunction (MGD): Poor lipid layer leads to rapid tear evaporation.
• Blepharitis: Inflammation of the eyelid margin that destabilizes the tear film.
• Medication‑induced dryness: Antihistamines, isotretinoin, antidepressants, and some glaucoma drops.
• Environmental exposure: Low humidity, wind, air‑conditioned or heated indoor air.
• Vitamin A deficiency: Impairs mucin production, leading to a “dry, scaly” conjunctiva.
• Post‑radiation or chemotherapy ocular surface damage: Toxic effect on lacrimal glands.
• Contact lens wear (especially extended wear): Disrupts tear exchange and can precipitate dryness.
• Autoimmune disorders besides Sjögren’s: Rheumatoid arthritis, systemic lupus erythematosus.
• Neurotrophic keratopathy: Reduced corneal sensation leads to reduced blink reflex and tear spread.

Associated Symptoms

Patients with xerophthalmic conjunctivitis often notice a constellation of eye‑related complaints. Common associated symptoms are:

• Persistent gritty or sand‑like sensation.
• Burning, stinging, or itching.
• Redness (hyperemia) of the conjunctiva.
• Blurred vision that improves with blinking.
• Fluctuating visual acuity, especially after prolonged screen time.
• Sensitivity to light (photophobia).
• Mucous or stringy discharge that may appear crusted on awakening.
• Feeling of foreign body in the eye.
• Dry patches or “scales” on the conjunctiva, sometimes described as “snow‑flake” lesions.

When to See a Doctor

While mild dryness can often be managed with over‑the‑counter lubricants, certain signs warrant professional evaluation:

• Symptoms persisting longer than 2 weeks despite regular artificial‑tear use.
• New or worsening redness, especially if it spreads across the entire eye.
• Noticeable discharge that is yellow, green, or foul‑smelling (possible infection).
• Sudden decrease in vision or persistent blurry vision.
• Eye pain that is deep, throbbing, or associated with headache.
• History of autoimmune disease, recent radiation therapy, or systemic medication known to cause dryness.

If any of these occur, schedule an appointment with an ophthalmologist or optometrist promptly.

Diagnosis

Eye care professionals use a stepwise approach to confirm xerophthalmic conjunctivitis and uncover the root cause.

History & Symptom Review

• Duration, triggers, and severity of dryness.
• Medication list, systemic illnesses, and occupational exposures.
• Contact‑lens wear habits and ocular hygiene practices.

Physical Examination

• Slit‑lamp biomicroscopy: Allows close inspection of the conjunctiva, cornea, and lid margins for signs of inflammation, staining, or scarring.
• Fluorescein staining: Highlights areas of epithelial breakdown on the cornea and conjunctiva.
• Schirmer test: Measures aqueous tear production using a filter paper strip placed under the lower lid.
• Tear Break‑Up Time (TBUT): Evaluates tear film stability; a time <10 seconds is abnormal.
• Lipid layer assessment: Interferometry or meibography to examine meibomian gland health.

Laboratory & Imaging Tests (when indicated)

• Serologic tests for Sjögren’s (anti‑SSA/Ro, anti‑SSB/La), rheumatoid factor, ANA.
• Vitamin A levels if deficiency is suspected.
• Ocular surface imaging (OCT, confocal microscopy) for severe cases.

Treatment Options

Therapy is aimed at restoring a stable tear film, reducing inflammation, and addressing any underlying systemic condition. Treatment is usually individualized and may combine several modalities.

Artificial Tears & Lubricants

• Preservative‑free drops (e.g., Refresh Optive, Systane Ultra) used 4–6 times daily.
• Gel or ointment formulations at night for prolonged coating.

Anti‑Inflammatory Medications

• Topical corticosteroids: Short courses (e.g., prednisolone acetate) for acute inflammation, tapered to avoid cataract or glaucoma risk.
• Cycloplegic agents: Low‑dose cyclosporine eye drops (Restasis) or lifitegrast (Xiidra) to improve tear production and reduce ocular surface inflammation.
• Oral steroids or immunomodulators: Reserved for systemic autoimmune disease flare‑ups.

Meibomian Gland & Lid‑Margin Care

• Warm compresses (5–10 minutes) followed by gentle lid massage.
• Lid hygiene scrubs with diluted baby shampoo or commercial lid wipes.
• In‑office meibomian gland expression or intense pulsed light (IPL) therapy for refractory MGD.

Environmental & Lifestyle Adjustments

• Humidifier use in dry indoor environments (30–50 % humidity).
• Avoid direct airflow from fans, air‑conditioners, or heating vents.
• Take regular breaks during screen work (20‑20‑20 rule).
• Protect eyes with wrap‑around sunglasses outdoors.

Systemic Management

• Address underlying autoimmune disease (e.g., hydroxychloroquine for Sjögren’s).
• Correct vitamin A deficiency with dietary counseling or supplementation (under physician guidance).
• Review and adjust systemic medications that contribute to dryness.

Procedural Options (for severe or refractory cases)

• Autologous serum eye drops – contain growth factors that promote epithelial healing.
• Punctal plugs – silicone or collagen inserts that block tear drainage, increasing ocular surface moisture.
• Amniotic membrane transplantation – for extensive conjunctival damage.

Prevention Tips

While some risk factors (age, genetics) cannot be changed, many lifestyle and ocular‑care habits can reduce the likelihood of developing xerophthalmic conjunctivitis.

• Maintain optimal hydration – aim for ≈ 2 L of water daily.
• Adopt a balanced diet rich in omega‑3 fatty acids (fatty fish, flaxseed) which may improve meibomian gland function.
• Limit or discontinue medications that cause dryness after discussing alternatives with your clinician.
• Practice meticulous eyelid hygiene, especially if you have blepharitis or MGD.
• Use preservative‑free artificial tears proactively if you spend many hours before a screen.
• Wear protective eyewear in windy, dusty, or smoky environments.
• Schedule routine eye examinations at least once a year, or more often if you have known risk factors.

Emergency Warning Signs

Key Take‑aways

Xerophthalmic conjunctivitis is a dry‑eye–related inflammation of the conjunctiva that can cause discomfort, visual disturbance, and increased infection risk. Recognizing the underlying cause—whether it be autoimmune, meibomian gland dysfunction, medication side effects, or environmental factors—is critical for effective treatment. Prompt evaluation by an eye‑care professional, appropriate anti‑inflammatory therapy, diligent lid hygiene, and lifestyle modifications typically provide relief and protect vision. Never ignore sudden pain or vision loss; these are red‑flag emergencies.

---

References:
1. Mayo Clinic. “Dry eye.” https://www.mayoclinic.org.
2. American Academy of Ophthalmology. “Conjunctivitis.” https://www.aao.org.
3. National Eye Institute (NIH). “Sjogren’s Syndrome and Dry Eye.” https://www.nei.nih.gov.
4. Cleveland Clinic. “Meibomian Gland Dysfunction.” https://my.clevelandclinic.org.
5. World Health Organization. “Vitamin A deficiency.” https://www.who.int.

```